Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study

被引：1

作者：

Arnaud, Alix ^{[1
,6
]}

Schilsky, Samantha ^{[2
]}

Lucia, Jackie ^{[2
]}

Maia, Marta ^{[3
]}

Laredo, Fernando ^{[4
]}

Marques, Ana Paula ^{[4
]}

Okada, Hikaru ^{[5
]}

Roberts, Andrew W. ^{[2
]}

机构：

[1] Sanofi, Boston, MA USA

[2] Aetion Inc, New York, NY USA

[3] Sanofi, Lisbon, Portugal

[4] Sanofi, Sao Paulo, Brazil

[5] Sanofi KK, Tokyo, Japan

[6] Sanofi, 450 Water St, Cambridge, MA 02141 USA

来源：

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2024年 / 30卷

关键词：

caplacizumab; healthcare resource utilization; hospital costs; immune thrombotic thrombocytopenic purpura; real-world evidence; TTP;

D O I：

10.1177/10760296241241525

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

European real-world data indicate that front-line treatment with caplacizumab is associated with improved clinical outcomes compared with delayed caplacizumab treatment. The objective of the study was to describe the characteristics, treatment patterns, and outcomes in hospitalized patients with an immune-mediated thrombotic thrombocytopenic purpura (iTTP) episode treated with front-line versus delayed caplacizumab in the US. This retrospective cohort analysis of a US hospital database included adult patients (>= 18 years) with an acute iTTP episode (a diagnosis of thrombotic microangiopathy and >= 1 therapeutic plasma exchange [TPE] procedure) from January 21, 2019, to February 28, 2021. Unadjusted baseline characteristics, treatment patterns, healthcare resource utilization, and costs were compared between patients who received front-line versus delayed (<2 vs >= 2 days after TPE initiation) caplacizumab treatment. Out of 39 patients, 16 (41.0%) received front-line and 23 (59.0%) received delayed treatment with caplacizumab. Baseline characteristics and symptoms were similar between the two groups. Patients who received front-line caplacizumab treatment had significantly fewer TPE administrations (median: 5.0 vs 12.0); and a significantly shorter hospital stay (median: 9.0 days vs 16.0 days) than patients receiving delayed caplacizumab therapy. Both of these were significantly lower in comparison of means (t-test P < .01). Median inpatient costs (inclusive of caplacizumab costs) were 54% higher in the delayed treated patients than in the front-line treated patients (median: $112 711 vs $73 318). TPE-specific cost was lower in the front-line treated cohort (median: $6 989 vs $10 917). In conclusion, front-line treatment with caplacizumab had shorter hospitalizations, lower healthcare resource utilization, and lower costs than delayed caplacizumab treatment after TPE therapy.

引用

页数：10

共 28 条

[21]

Sullivan SD., 2023, AM SOC HEM ANN M

[22] Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience [J].

Tse, Brandon ;

Buchholz, Megan ;

Pavenski, Katerina .

PLATELETS, 2023, 34 (01)

[23] Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs [J].

Ulrichts, Hans ;

Silence, Karen ;

Schoolmeester, Anne ;

de Jaegere, Peter ;

Rossenu, Stefaan ;

Roodt, Jan ;

Priem, Sofie ;

Lauwereys, Marc ;

Casteels, Peter ;

Van Bockstaele, Femke ;

Verschueren, Katrien ;

Stanssens, Patrick ;

Baumeister, Judith ;

Holz, Josefin-Beate .

BLOOD, 2011, 118 (03) :757-765

[24] Thrombotic thrombocytopenic purpura and its diagnosis [J].

Veyradier, A ;

Meyer, D .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (11) :2420-2427

[25] Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura [J].

Voelker, Linus A. ;

Kaufeld, Jessica ;

Balduin, Gesa ;

Merkel, Lena ;

Kuehne, Lucas ;

Eichenauer, Dennis A. ;

Osterholt, Thomas ;

Haegele, Holger ;

Kann, Martin ;

Grundmann, Franziska ;

Kolbrink, Benedikt ;

Schulte, Kevin ;

Gaeckler, Anja ;

Kribben, Andreas ;

Boss, Kristina ;

Potthoff, Sebastian A. ;

Rump, Lars C. ;

Schmidt, Tilman ;

Muehlfeld, Anja S. ;

Schulmann, Karsten ;

Hermann, Matthias ;

Gaedeke, Jens ;

Sauerland, Kristin ;

Bramstedt, Joern ;

Hinkel, Ulrich P. ;

Miesbach, Wolfgang ;

Bauer, Frederic ;

Westhoff, Timm H. ;

Bruck, Heike ;

Buxhofer-Ausch, Veronika ;

Mueller, Tobias J. ;

Wendt, Ralph ;

Harth, Ana ;

Schreiber, Adrian ;

Seelow, Evelyn ;

Toelle, Markus ;

Gohlisch, Christopher ;

Bieringer, Markus ;

Geuther, Gesa ;

Jabs, Wolfram J. ;

Fischereder, Michael ;

von Bergwelt-Baildon, Anke ;

Schoenermarck, Ulf ;

Knoebl, Paul ;

Menne, Jan ;

Brinkkoetter, Paul T. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (03) :559-572

[26] Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population [J].

Wahl, Peter M. ;

Terrell, Deirdra R. ;

George, James N. ;

Rodgers, J. Keith ;

Uhl, Lynn ;

Cataland, Spero ;

Bohn, Rhonda L. .

THROMBOSIS AND HAEMOSTASIS, 2010, 103 (06) :1203-1209

[27] ISTH guidelines for treatment of thrombotic thrombocytopenic purpura [J].

Zheng, X. Long ;

Vesely, Sara K. ;

Cataland, Spero R. ;

Coppo, Paul ;

Geldziler, Brian ;

Iorio, Alfonso ;

Matsumoto, Masanori ;

Mustafa, Reem A. ;

Pai, Menaka ;

Rock, Gail ;

Russell, Lene ;

Tarawneh, Rawan ;

Valdes, Julie ;

Peyvandi, Flora .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (10) :2496-2502

[28] ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura [J].